Mohini Ranganathan, MBBS
Associate Professor of PsychiatryCards
About
Research
Publications
2026
An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol
P. A. Costa G, Sofuoglu M, Compton P, Ranganathan M, Pittman B, De Aquino J. An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol. Neuropsychopharmacology 2026, 1-10. PMID: 42162267, PMCID: PMC13213852, DOI: 10.1038/s41386-026-02443-w.Peer-Reviewed Original ResearchBaseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers — A “Disordinal” Effect
Cecchi M, Johannesen J, Farley B, Quirk M, Mahmoud-Zadeh M, Uslaner J, Terry-Lorenzo R, Smith D, Ruhl D, Rotte M, Reese A, O'Donnell P, Mollon J, Missling C, Matsuoka Y, Marino M, Lee S, Korolev I, Klamer D, Jeong A, Honda S, Fadem K, Doherty J, Cohen E, Christensen S, Chadchankar H, Buhl D, Adachi M, D'Souza D, Hamilton H, Ranganathan M, Roach B, Ereshefsky L, Walling D, Potter W, Javitt D, Mathalon D. Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers — A “Disordinal” Effect. Biological Psychiatry 2026 PMID: 41997476, DOI: 10.1016/j.biopsych.2026.03.1008.Peer-Reviewed Original ResearchSponsorship and Career Advancement for Asian Medical Faculty
Sebastian D, Herrera K, Ranganathan M, Landeros-Weisenberger A, Latimore D. Sponsorship and Career Advancement for Asian Medical Faculty. JAMA Network Open 2026, 9: e2553241. PMID: 41511770, PMCID: PMC12789948, DOI: 10.1001/jamanetworkopen.2025.53241.Peer-Reviewed Original Research
2025
Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD
Valizadeh A, Roache J, Zhang X, Hu Y, Gueorguieva R, Averill L, Ranganathan M, Wang Z, Williamson D, Shiroma P, Girgenti M, Petrakis I, López-Roca A, Young-McCaughan S, Keane T, Peterson A, Abdallah C, Krystal J, Xu K, PTSD F. Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD. IScience 2025, 29: 114445. PMID: 41561376, PMCID: PMC12814687, DOI: 10.1016/j.isci.2025.114445.Peer-Reviewed Original ResearchA translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam A, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray D, Grinband J, Gur R, Haubold N, Heffernan Z, Heneks M, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro N, Schutte C, Selloni A, Van Snellenberg J, Surti T, Wolf D, Zharyy C, Group T, Abi-Dargham A, Gur R, Lieberman J, Kantrowitz J, Anticevic A, Cho Y, Krystal J. A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial. Journal Of Psychiatric Research 2025, 194: 196-210. PMID: 41519104, PMCID: PMC13138834, DOI: 10.1016/j.jpsychires.2025.12.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsArtificial Intelligence in Depression-Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep-Learning-Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management.
Benrimoh D, Whitmore K, Richard M, Golden G, Perlman K, Jalali S, Friesen T, Barkat Y, Mehltretter J, Fratila R, Armstrong C, Israel S, Popescu C, Karp J, Parikh S, Golchi S, Moodie E, Shen J, Gifuni A, Ferrari M, Sapra M, Kloiber S, Pinard G, Dunlop B, Looper K, Ranganathan M, Enault M, Beaulieu S, Rej S, Hersson-Edery F, Steiner W, Anacleto A, Qassim S, McGuire-Snieckus R, Margolese H. Artificial Intelligence in Depression-Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep-Learning-Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management. The Journal Of Clinical Psychiatry 2025, 86 PMID: 40875536, DOI: 10.4088/jcp.24m15634.Peer-Reviewed Original ResearchThe Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review
Shafie M, Ing K, Rostam‐Abadi Y, Weleff J, Griffin M, Ranganathan M, Aghaei A, Pratt N, Funaro M, Nia A. The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review. Addiction Biology 2025, 30: e70047. PMID: 40415392, PMCID: PMC12104536, DOI: 10.1111/adb.70047.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, De Aquino J, Bassir Nia A, Ranganathan M. Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study. Psychopharmacology 2024, 241: 2145-2155. PMID: 38832949, PMCID: PMC12954630, DOI: 10.1007/s00213-024-06625-6.Peer-Reviewed Original ResearchClinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
Pfeiffer P, Geller J, Ganoczy D, Jagusch J, Carty J, Festin F, Gilmer W, Martis B, Ranganathan M, Wiechers I, Hosanagar A. Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38206011, DOI: 10.4088/jcp.23m14984.Peer-Reviewed Original Research
2023
Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing
Martin A, Ranganathan M, D’Souza D. Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing. 2023, 156-166. DOI: 10.1017/9781108943246.017.Books
Clinical Trials
Current Trials
Brain Changes and Cannabis Use Study
IRB ID2000032181RoleSub InvestigatorPrimary Completion Date05/31/2027Recruiting ParticipantsGenderBothAge18 years - 75 yearsM1 Schizophrenia PET Study
IRB ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsSchizophrenia Spectrum Biomarkers Consortium (SSBC)
IRB ID2000029485RolePrincipal InvestigatorPrimary Completion Date12/31/2030Recruiting ParticipantsImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
IRB ID1005006735RoleSub InvestigatorPrimary Completion Date12/31/2016Recruiting ParticipantsGenderMaleAge18 years - 55 yearsA longitudinal study of the effects of cannabis exposure on neuro-development in adolescents and young adults
IRB ID2000024543RoleSub InvestigatorPrimary Completion Date01/31/2021Recruiting ParticipantsGenderBothAge13 years - 25 years
Academic Achievements & Community Involvement
News & Links
Media
YC-SCAN2 January 2026 Webinar
The January 2026 YC-SCAN2 webinar titled “Sex Differences in Cannabinoid Pharmacology” featured Dr. Mohini Ranganathan, Associate Professor of Psychiatry at Yale School of Medicine. Dr. Ranganathan presented an in-depth overview of sex differences in cannabinoid pharmacology, highlighting longstanding research gaps related to the historical underrepresentation of women in cannabis studies and recent efforts to address these disparities. Drawing on over two decades of research, she discussed biological and clinical factors underlying sex-specific responses to cannabinoids, including differences in receptor availability, hormonal influences, and patterns of cannabis use. Her presentation emphasized emerging human laboratory and PET imaging data, showing that women may be more sensitive to the rewarding effects of THC at lower doses, and underscored the critical need for intentional, sex-specific and interdisciplinary approaches in future cannabinoid research.
News
- May 21, 2026Source: Neuropsychopharmacology
An Opioid-Withholding Human Laboratory Paradigm During Opioid Agonist Treatment for Opioid Use Disorder and Chronic Pain: Phase- and Dose-Dependent Effects of Cannabidiol
- February 11, 2026Source: iScience
Combining DNA Methylation Features and Clinical Characteristics Predicts Ketamine Treatment Response for PTSD
- January 14, 2026Source: JAMA Network Open
Sponsorship and Career Advancement for Asian Medical Faculty
- February 28, 2025Source: Yale Ventures
YSM Faculty Win Awards From the Blavatnik Fund for Innovation at Yale